What is the address of Dr. Caroline Schelstraete, Neurologie?

The registered office of Dr. Caroline Schelstraete, Neurologie is located at Lauwstraat 60, 9051 Gent.

Is Dr. Caroline Schelstraete, Neurologie still active?

Yes. According to the CBE (30 October 2026) Dr. Caroline Schelstraete, Neurologie is active, legal situation “Normale toestand”, started on 2 November 2018.

Is Dr. Caroline Schelstraete, Neurologie registered on Peppol?

Yes, Dr. Caroline Schelstraete, Neurologie is registered on the Peppol network with ID 0208:0712787177.

What is the enterprise number of Dr. Caroline Schelstraete, Neurologie?

The enterprise number of Dr. Caroline Schelstraete, Neurologie is BE0712787177.

When was Dr. Caroline Schelstraete, Neurologie founded?

Dr. Caroline Schelstraete, Neurologie was founded on 2 November 2018.

Who are the directors of Dr. Caroline Schelstraete, Neurologie?

According to the 2025 annual accounts, the directors of Dr. Caroline Schelstraete, Neurologie are: Caroline Schelstraete.

Is Dr. Caroline Schelstraete, Neurologie a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 2 November 2018; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Dr. Caroline Schelstraete, Neurologie make in 2025?

Dr. Caroline Schelstraete, Neurologie posted a profit after taxes of € 198,721 in financial year 2025.

What is the revenue of Dr. Caroline Schelstraete, Neurologie?

As a small company, Dr. Caroline Schelstraete, Neurologie is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 261,172.

Dr. Caroline Schelstraete, Neurologie (Private Limited)

Dossier Dr. Caroline Schelstraete, Neurologie, printed on 30 October 2026 from databakkes.be/en/0712787177/dr-caroline-schelstraete-neurologie. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Dr. Caroline Schelstraete, Neurologie from Gent, company number BE0712787177, closed financial year 2025 with a result of € 198,721 after tax. For that financial year Dr. Caroline Schelstraete, Neurologie recorded a gross margin of € 261,172 and equity of € 127,321. Compared with financial year 2024, the result moved from € 139,186 to € 198,721. Profitable, and profit is growing. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 30, 2026.

What it is worth Healthy

€ 127,321

▼ 19% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 198,721

▲ 43% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 147,739

▼ 50% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 229,186 paid out

More than the year’s profit went to the shareholders; reserves fell.

Debts at end 2025

Bank debt

€ 88,000

▼ 28% vs 2024

Loans from banks and other lenders, long and short.

Wages and social charges

€ 16,401

▼ 29% vs 2024

Wages, holiday pay and social contributions still to pay. No outstanding taxes.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 116,665 Gross margin 2022: € 116,665 First fiscal year in the series	€ 185,550 Gross margin 2023: € 185,550 ▲ 59% vs 2022 (€ 116,665) Favourable step	€ 182,791 Gross margin 2024: € 182,791 ▼ 1% vs 2023 (€ 185,550) Unfavourable step	€ 261,172 Gross margin 2025: € 261,172 ▲ 43% vs 2024 (€ 182,791) Favourable step	▲ 43%
Profit after taxes	€ 90,284 Profit after taxes 2022: € 90,284 First fiscal year in the series	€ 140,785 Profit after taxes 2023: € 140,785 ▲ 56% vs 2022 (€ 90,284) Favourable step	€ 139,186 Profit after taxes 2024: € 139,186 ▼ 1% vs 2023 (€ 140,785) Unfavourable step	€ 198,721 Profit after taxes 2025: € 198,721 ▲ 43% vs 2024 (€ 139,186) Favourable step	▲ 43%
Equity	€ 108,084 Equity 2022: € 108,084 First fiscal year in the series	€ 159,385 Equity 2023: € 159,385 ▲ 47% vs 2022 (€ 108,084) Favourable step	€ 157,786 Equity 2024: € 157,786 ▼ 1% vs 2023 (€ 159,385) Unfavourable step	€ 127,321 Equity 2025: € 127,321 ▼ 19% vs 2024 (€ 157,786) Unfavourable step	▼ 19%
Total debts	€ 27,910 Total debts 2022: € 27,910 First fiscal year in the series	€ 63,520 Total debts 2023: € 63,520 ▲ 128% vs 2022 (€ 27,910) Unfavourable step	€ 145,789 Total debts 2024: € 145,789 ▲ 130% vs 2023 (€ 63,520) Unfavourable step	€ 104,809 Total debts 2025: € 104,809 ▼ 28% vs 2024 (€ 145,789) Favourable step	▼ 28%
Cash	€ 134,316 Cash 2022: € 134,316 First fiscal year in the series	€ 221,605 Cash 2023: € 221,605 ▲ 65% vs 2022 (€ 134,316) Favourable step	€ 297,880 Cash 2024: € 297,880 ▲ 34% vs 2023 (€ 221,605) Favourable step	€ 147,739 Cash 2025: € 147,739 ▼ 50% vs 2024 (€ 297,880) Unfavourable step	▼ 50%
Retained profit	€ 89,484 Retained profit 2022: € 89,484 First fiscal year in the series	€ 140,785 Retained profit 2023: € 140,785 ▲ 57% vs 2022 (€ 89,484) Favourable step	€ 139,186 Retained profit 2024: € 139,186 ▼ 1% vs 2023 (€ 140,785) Unfavourable step	€ 108,721 Retained profit 2025: € 108,721 ▼ 22% vs 2024 (€ 139,186) Unfavourable step	▼ 22%
Dividend	€ 264,645 Dividend 2022: € 264,645 First fiscal year in the series	€ 89,484 Dividend 2023: € 89,484 ▼ 66% vs 2022 (€ 264,645) Unchanged	€ 140,785 Dividend 2024: € 140,785 ▲ 57% vs 2023 (€ 89,484) Unchanged	€ 229,186 Dividend 2025: € 229,186 ▲ 63% vs 2024 (€ 140,785) Unchanged	▲ 63%
Bank debt	€ 0 Bank debt 2022: € 0 First fiscal year in the series	€ 0 Bank debt 2023: € 0 Unchanged (€ 0) Unchanged	€ 122,540 Bank debt 2024: € 122,540 Unchanged (€ 0) Unfavourable step	€ 88,000 Bank debt 2025: € 88,000 ▼ 28% vs 2024 (€ 122,540) Favourable step	▼ 28%
Balance sheet total	€ 135,994 Balance sheet total 2022: € 135,994 First fiscal year in the series	€ 222,905 Balance sheet total 2023: € 222,905 ▲ 64% vs 2022 (€ 135,994) Unchanged	€ 303,575 Balance sheet total 2024: € 303,575 ▲ 36% vs 2023 (€ 222,905) Unchanged	€ 232,130 Balance sheet total 2025: € 232,130 ▼ 24% vs 2024 (€ 303,575) Unchanged	▼ 24%

Key figures of Dr. Caroline Schelstraete, Neurologie, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Dr. Caroline Schelstraete, Neurologie?

What happened at Dr. Caroline Schelstraete, Neurologie in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 30, 2026 New annual accounts for financial year 2025: profit of € 198,721 (▲ 43% vs 2024). Source: NBB ↗
Nov 2, 2018 New establishment in Gent. KBO
Nov 2, 2018 Start of the company according to the CBE. KBO

In short

From € 90,284 profit in 2022 to € 198,721 profit in 2025.

Paid € 171,063 in corporate taxes since 2022.

Best year ever: 2025, with € 198,721 profit.

Paid out € 724,101 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Caroline Schelstraete

Dr. Caroline Schelstraete, Neurologie

Neurologie AZORG

Behind Dr. Caroline Schelstraete, Neurologie is Caroline Schelstraete. Caroline Schelstraete is also behind Neurologie AZORG.

Directors

According to the 2025 annual accounts

Caroline Schelstraete

Director

Also active at: Neurologie AZORG

Establishments

Establishment units

Physical locations of this company

Registered office

Lauwstraat 60

9051 Gent

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0712.787.177
VAT number: BE 0712.787.177
Registered office: Lauwstraat 60, 9051 Gent
Names & denominations: Dr. Caroline Schelstraete, Neurologie
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 2 November 2018
Peppol: Active · Active since 5 Jan 2026

View on CBE Public ↗ Annual accounts (NBB) ↗